细胞色素P450基因多态性与药物性肝损伤的关系

王巧玲; 邹正升

doi:10.3969/j.issn.1001-5256.2020.05.045

细胞色素P450基因多态性与药物性肝损伤的关系

DOI: 10.3969/j.issn.1001-5256.2020.05.045

1. 北京大学医学部
2. 解放军总医院第五医学中心非感染性肝病诊疗与研究中心

基金项目:

国家自然科学基金项目（81670527）；

详细信息

中图分类号: R575
计量
- 文章访问数: 1007
- HTML全文浏览量: 35
- PDF下载量: 173
- 被引次数: 0
出版历程
- 出版日期: 2020-05-20

Association between cytochrome P450 gene polymorphism and drug-induced liver injury

Peking University Health Science Center, Beijing 100071, China

Research funding:

摘要

摘要:
随着药物性肝损伤患病率的逐年上升,药物性肝损伤发病机制成为了关注的焦点。CYP450酶作为一个庞大的家族,参与了药物在人体肝脏内的几乎所有氧化代谢反应。近年来发现CYP450酶的基因多态性导致了药效动力学在不同个体中的代谢差异性,故探索CYP450酶基因多态性在药物性肝损伤中的作用,可促进对药物性肝损伤发病机制的了解。对已发现与药物性肝损伤相关的CYP450酶基因多态性进行综述。
- 细胞色素P450酶系统 /
- 多态现象,遗传 /
- 化学性与药物性肝损伤
Abstract:
As the prevalence rate of drug-induced liver injury increases year by year, the pathogenesis of drug-induced liver injury has become the focus of attention. As a large family, CYP450 enzymes participate in almost all oxidative metabolic reactions of drugs in the human liver. Recent studies have shown that CYP450 enzyme gene polymorphisms lead to the differences in pharmacodynamics between individuals, and therefore, exploring the role of CYP450 enzyme gene polymorphisms in drug-induced liver injury may promote the understanding of the pathogenesis of drug-induced liver injury. This article reviews the CYP450 enzyme polymorphisms that have been found to be associated with drug-induced liver injury.
- cytochrome P-450 enzyme system /
- polymorphism,genetic /
- chemical and drug induced liver injury

HTML全文

参考文献(43)

[1] BJÖRNSSON ES, BERGMANN OM, BJÖRNSSON HK, et al.Incidence, presentation, and outcomes in patients with druginduced liver injury in the general population of Iceland[J].Gastroenterology, 2013, 144(7):1419-1425, 1425. e1-e3; quiz e19-e20.

[2] MIGUEL A, AZEVEDO LF, ARAU'JO M, et al. Frequency of adverse drug reactions in hospitalized patients:A systematic review and meta-analysis[J]. Pharmacoepidemiol Drug Saf,2012, 21(11):1139-1154.

[3] LI L, JIANG W, WANG JY, et al. Clinical analysis of acute drug induced liver disease in 275 cases[J]. J Clin Hepatol,2009, 25(1):44-46.(in Chinese）李蕾，蒋炜，王吉耀，等．275例急性药物性肝病临床分析[J]．临床肝胆病杂志，2009, 25(1):44-46.

[4] European Association for the Study of the Liver. EASL Clinical Practice Guidelines:Drug-induced liver injury[J]. J Hepatol, 2019, 70(6):1222-1261.

[5] ZHANG RY, YANG Y, ZOU LY, et al. The study on CYP2D6、CYP3A5、CYP1A2 genetic polymorphism in Chinese Han population[J]. J Psychiatry, 2018, 31(2):129-132.(in Chinese）张仁云，杨楹，邹连勇，等．中国汉族人群CYP2D6、CYP3A5、CYP1A2基因多态性研究[J]．精神医学杂志，2018, 31(2):129-132.

[6] REN GY, WANG JJ, ZHANG RL et al. Effect of aconitum vilmorimianum kom liquor on rat Liver CYP1A2, CYP3A1 and CYP2E1 by cocktail probe[J]. J Henan Univ Sci Tech:Med Sci, 2016, 34(4):289-293.(in Chinese）任国印，王晶晶，张瑞林，等．探针药物法评价黄草乌酒对大鼠肝脏CYP1A2、CYP3A1和CYP2E1的影响[J]．河南科技大学学报医学版，2016, 34(4):289-293.

[7] YANG AH, ZHANG L, ZHI DX, et al. Identification and analysis of the reactive metabolites related to the hepatotoxicity of safrole[J]. Xenobiotica, 2018, 48(11):1164-1172.

[8] ZHANG YL, CUI YQ, WANG XS, et al. Experimental study on effect of Astragalus granules and Astragalus injection on enzymatic activities[J]. Chin Pharmacol Bull, 2013, 29(4):512-519.(in Chinese）张咏莉，崔玉强，汪向升，等．黄芪颗粒和黄芪注射液对CYP1A2、CYP2D、CYP2C亚酶活性影响的实验研究[J]．中国药理学通报，2013, 29(4):512-519.

[9] PU X, GAO Y, LI R, et al. Biomarker discovery for cytochrome P450 1A2 activity assessment in rats, based on metabolomics[J]. Metabolites, 2019, 9(4):e77.

[10] ALMANSOUR MI, JARRAR YB, JARRAR BM. In vivo investigation on the chronic hepatotoxicity induced by sertraline[J].Environ Toxicol Pharmacol, 2018, 61:107-115.

[11] LIU R, QIN M, HANG P, et al. Effects of Panax notoginseng saponins on the activities of CYP1A2, CYP2C9, CYP2D6 and CYP3A4in rats in vivo[J]. Phytother Res, 2012, 26(8):1113-1118.

[12] KOU HJ, DENG J, ZHU CZ, et al. Effect of CYP2C9 and VKORC1 gene polymorphism on warfarin steady-state therapeutic dose and individual[J]. J Shanxi Med Univ, 2017, 48(11):1102-1107.(in Chinese）寇惠娟，邓捷，朱参战，等，CYP2C9和VKORC1基因多态性对华法林稳态治疗剂量及个体化抗凝疗效的影响[J]．山西医科大学学报，2017, 48(11):1102-1107.

[13] MA JX, MA LQ, LIU C, et al. The effects of CYP2C9 and CYP2C19gene polymorphisms on maintenance dosage of Warfarin in elderly patients with nonvalvular atrial fibrillation[J]. Chin J Med Offic,2018, 46(5):540-543.(in Chinese）马建新，马丽群，刘畅，等．CYP2C9与CYP2C19基因多态性对老年非瓣膜性心房颤动患者华法林维持剂量影响[J]．临床军医杂志，2018, 46(5):540-543.

[14] WANG R, ZHANG H, WANG Y, et al. Effects of salvianolic acid B and tanshinone IIA on the pharmacokinetics of losartan in rats by regulating the activities and expression of CYP3A4and CYP2C9[J]. J Ethnopharmacol, 2016, 180:87-96.

[15] SINGH H, LATA S, NEMA V, et al. CYP1A1m1 and CYP2C9∗2and∗3 polymorphism and risk to develop ARV-associated hepatotoxicity and its severity[J]. APMIS, 2017, 125(6):523-535.

[16] YANG R, LIU H, CHEN ZH. Clinical pharmacists use CYP2C19genotyping test to guide individual medication therapy of Clopidogrel and to evaluate the efficacy of treatment[J]. Chin J Clin Pharmacol Ther, 2019, 24(8):938-943.(in Chinese）杨瑞，刘慧，陈泽姮，等．临床药师基于CYP2C19基因检测指导氯吡格雷个体化用药及其疗效评价[J]．中国临床药理学与治疗学，2019, 24(8):938-943.

[17] ZHAI Y, WANG L, YANG F, et al. The mechanism and risk factors of clopidogrel-induced liver injury[J]. Drug Chem Toxicol, 2016, 39(4):367-374.

[18] WU ZT, WEI YY, XIAO L, et al. Relationship between polymorphism of CYP2C19 gene and changes of liver function induced by antidepressants[J]. J Clin Psychiatry, 2019, 29(1):60-62.(in Chinese）吴作天，魏艳艳，肖玲，等．肝药酶CYP2C19基因多态性与抗抑郁药所致肝功能改变的关系[J]．临床精神医学杂志，2019,29(1):60-62.

[19] HU X, ZHANG M, BAI H, et al. Antituberculosis drug-induced adverse events in the liver, kidneys, and blood:Clinical profiles and pharmacogenetic predictors[J]. Clin Pharmacol Ther, 2018, 104(2):326-334.

[20] ZHANG J, ZHU X, LI Y, et al. Correlation of CpG island methylation of the cytochrome P450 2E1/2D6 genes with liver injury induced by anti-tuberculosis drugs:A nested case-control study[J]. Int J Environ Res Public Health, 2016, 13(8):e776.

[21] ARAFA MH, ATTEIA HH. Genetic polymorphisms of cytochrome P450 2D6(CYP2D6)are associated with long term tramadol treatment-induced oxidative damage and hepatotoxicity[J]. Toxicol Appl Pharmacol, 2018, 346:37-44.

[22] LI Q, WANG R, GUO Y, et al. Influence of CYP2D6 genetic polymorphism on pharmacokinetics of tramadol in Chinese population[J]. Chin J Clin Pharmacol, 2009, 25(4):302-307.(in Chinese）李芹，王睿，郭雅，等．中国人群细胞色素P4502D6基因多态性对曲马多药代动力学的影响[J]．中国临床药理学杂志，2009,25(4):302-307.

[23] DEKKER SJ, DOHMEN F, VERMEULEN NPE, et al. Characterization of kinetics of human cytochrome P450s involved in bioactivation of flucloxacillin:Inhibition of CYP3A-catalysed hydroxylation by sulfaphenazole[J]. Arch Toxicol, 2018, 92(1):383-399.

[24] GUO TJ, LI YH, ZHU LY, et al. Association between CYP3A5∗3/CYP3A4∗18-B gene polymorphisms and liver injury induced by anti-tuberculosis[J]. Chin J Dis Control Prev, 2016, 20(9):897-900.(in Chinese）郭桐君，李玉红，朱凌妍，等．CYP3A5∗3和CYP3A4∗18B基因多态性与抗结核药物性肝损伤的关系[J]．中华疾病控制杂志，2016, 20(9):897-900.

[25] ZHAO DF, DONG Q. Research advances in genetic polymorphisms associated with susceptibility to anti-tuberculosis drug indued liver injury[J]. Med Recapitulate, 2019, 25(20):4002-4008.(in Chinese）赵德芳，董勤．与抗结核药物肝损伤易感性相关的基因多态性研究进展[J]．医学综述，2019, 25(20):4002-4008.

[26] QIU XY, WU Z, XU LY, et al. Influence of CYP3A4, CYP3A5and CYP3A7 polymorphisms on tacrolimus pharmacokinetics in Chinese renal transplant patients[J]. Chin J Pharmacoepidemiol, 2019, 28(7):451-455.(in Chinese）邱晓燕，武卓，徐璐扬，等．CYP3A4、CYP3A5和CYP3A7的基因多态性对中国汉族肾移植患者他克莫司药动学的影响[J]．药物流行病学杂志，2019, 28(7):451-455.

[27] TOLOSA L, JIMENEZ N, PEREZ G, et al. Customised in vitro model to detect human metabolism-dependent idiosyncratic drug-induced liver injury[J]. Arch Toxicol, 2018, 92(1):383-399.

[28] CHEN CW, Research advances in drug-induced liver injury and existing problems in China[J]. J Clin Hepatol, 2018, 34(6):1147-1151.(in Chinese）陈成伟．药物性肝损伤的研究进展及我国存在的问题[J]．临床肝胆病杂志，2018, 34(6):1147-1151.

[29] LIN YX, HE XB. Clinical features of drug-induced liver injury and related risk factors[J]. J Clin Hepatol, 2018, 34(6):1237-1241.(in Chinese）林云霞，何晓彬．药物性肝损伤的临床特点及危险因素分析[J]．临床肝胆病杂志，2018, 34(6):1237-1241.

[30] TU C, GE FL, GUO YM, et al. Analysis of clinical characteristics and medication rationality of polygonum multiflorum thunb.and its preparation-related liver injury[J]. Chin J Pharmacov, 2019, 16(5):270-276.(in Chinese）涂灿，葛斐林，郭玉明，等．何首乌相关肝损伤临床特征及用药合理性分析[J]．中国药物警戒，2019, 16(5):270-276.

[31] WANG ZJ, LI H, LI DK, et al. Effects of aqueous extract of Polygoni Multiflori Radix and its main constituents on expression of mRNA of CYP1A2, CYP2C9, and CYP2E1 in human liver L02 cells[J]. Chin Tradit Herb Drugs, 2017, 48(23):4912-4920.(in Chinese）王子建，李浩，李登科，等．何首乌水提物及其主要成分对人肝细胞L02中CYP1A2、CYP2C9和CYP2E1 mRNA表达的影响[J]．中草药，2017, 48(23):4912-4920.

[32] WU S, YANG HL, LI H, et al. Prohibitive effect of processed polygonum multiflorum on CYP1A2 activities and mRNA expressions of rats[J]. World Chin Med, 2016, 11(3):475-478.(in Chinese）吴双，杨红莉，李浩，等．制何首乌对大鼠肝CYP1A2酶活性及mRNA表达的抑制作用[J]．世界中医药，2016, 11(3):475-478.

[33] METUSHI IG, SANDERS C, Acute Liver Study Group, et al.Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure[J].Hepatology, 2014, 59(3):1084-1093.

[34] SANTOS NP, CALLEGARI-JACQUES SM, RIBEIRO DOS SANTOS AK, et al. N-acetyl transferase 2 and cytochrome P450 2E1genes and isoniazid-induced hepatotoxicity in Brazilian patients[J]. Int J Tuberc Lung Dis, 2013, 17(4):499-504.

[35] RANA SV, SHARMA SK, OLA RP, et al. N-acetyltransferase2, cytochrome P4502E1 and glutathione S-transferase genotypes in antitubercular treatment-induced hepatotoxicity in North Indians[J]. J Clin Pharm Ther, 2014, 39(1):91-96.

[36] PERWITASARI DA, DARMAWAN E, MULYANI UA, et al. Polymorphisms of NAT2, CYP2E1, GST, and HLA related to drug-induced liver injury in indonesian tuberculosis patients[J].Int J Mycobacteriol, 2018, 7(4):380-386.

[37] DENG LL, WEI LQ, HAO JQ, et al. Anti-tuberculosis druginduced liver injury correlated with the methylation in the promoter regions of CYP2E1 and GSTM1[J]. J Med Postgraduates, 2019, 32(6):613-618.(in Chinese）邓乐乐，韦丽琴，郝金奇，等．药物代谢酶CYP2E1、GSTM1基因启动子区甲基化与抗结核药物性肝损伤的相关性研究[J]．医学研究生学报，2019, 32(6):613-618.

[38] ZHANG ZH. Study on the mechanisms of hepatotoxicity induced by isoniazid and rifampicin and the role of hepatic protective drugs[D]. Shijiazhuang:Hebei Medical University,2009:62-64.(in Chinese）张志华．异烟肼和利福平合用致肝细胞毒性及药物保护机制探讨[D]．石家庄：河北医科大学，2009:62-64.

[39] XIE W, JIANG Z, WANG J, et al. Protective effect of hyperoside against acetaminophen(APAP)induced liver injury through enhancement of APAP clearance[J]. Chem Biol Interact, 2016, 246:11-19.

[40] LIN, KOSTOV R, HUANG JT, et al. Novel pathways of ponatinib disposition catalyzed By CYP1A1 involving generation of potentially toxic metabolites[J]. J Pharmacol Exp Ther, 2017,363(1):12-19.

[41] LIN L, GUAN H, LI R, et al. Auriculatone sulfate effectively protects mice against acetaminophen-induced liver injury[J]. Molecules, 2019, 24(20):e3642.

[42] WANG C, WANG P, YANG LP, et al. Association of CYP2C9,CYP2A6, ACSM2A, and CPT1A gene polymorphisms with adverse effects of valproic acid in Chinese patients with epilepsy[J]. Epilepsy Res, 2017, 132:64-69.

[43] ZHAO M, ZHANG T, LI G, et al. Associations of CYP2C9 and CYP2A6 polymorphisms with the concentrations of valproate and its hepatotoxin metabolites and valproate-induced hepatotoxicity[J]. Basic Clin Pharmacol Toxicol, 2017, 121(2):138-143.

施引文献

资源附件(0)

访问统计